In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion ( 13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus. PRADAXA ® is a registered trademark of Boehringer Ingelheim Pharma GmbH and Co. KG and used under license. RE-LY ® is a registered service mark of Boehringer Ingelheim International GmbH and used under license. SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.